Please login to the form below

Not currently logged in
Email:
Password:

acute myeloid leukaemia

This page shows the latest acute myeloid leukaemia news and features for those working in and with pharma, biotech and healthcare.

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

For instance, it licensed CureVac ’s cancer vaccine CV9202 in 2014, formed a collaboration with Philogen seeking immunotherapies for acute myeloid leukaemia in 2015, and partnered an oncolytic virus therapy developed ... A key focus of that effort is

Latest news

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    Pfizer’ s leukaemia drug Mylotarg backed for use in EU. The CHMP’s positive opinion could see the drug return to market after almost eight years. ... Pfizer’s Mylotarg looks set to return to the EU market after a gap of several years, with the CHMP

  • Bad news for Innate Pharma as BMS-backed drug stumbles Bad news for Innate Pharma as BMS-backed drug stumbles

    It’s not the first disappointment in the lirilumab programme. Earlier this year, the anti-killer cell immunoglobulin-like receptor (KIR) antibody flunked the EffiKIR trial in acute myeloid leukaemia (AML),

  • FDA fast-tracks Astellas' Rydapt rival FDA fast-tracks Astellas' Rydapt rival

    The FDA gave the status to gilteritinib as a treatment for adults with FLT3-mutation-positive relapsed or refractory acute myeloid leukaemia (AML), a cancer that impacts blood and bone marrow.

  • Novartis gets EU nod for leukaemia drug Rydapt Novartis gets EU nod for leukaemia drug Rydapt

    Novartis has added EU approval its US registration for FLT3 inhibitor Rydapt, a new drug that brings years of stagnation in the development of new drugs for acute myeloid leukaemia (AML) ... AML is the most common form of acute leukaemia in adults and

  • AbbVie and Roche plan Venclexta combo filings in leukaemia AbbVie and Roche plan Venclexta combo filings in leukaemia

    AbbVie and Roche plan Venclexta combo filings in leukaemia. MURANO trial shows the duo’s treatment extends PFS. ... AbbVie and Roche have ambitions to extend the use of the drug into non-Hodgkin's lymphoma (NHL) and acute myeloid leukaemia (AML),

More from news
Approximately 2 fully matching, plus 80 partially matching documents found.

Latest Intelligence

  • Digital disruption Digital disruption

    Initially AZ and Microsoft have focused acute myeloid leukaemia (AML), simulating experiments to predict how drug combinations might be used to overcome resistance to drugs that target cell signalling in AML,

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase ... 1, 000. CoLucid. Lilly. Company acquisition.

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... Commercial milestones of up to $150m. Lead product has completed phase II in acute myeloid leukaemia.

  • Deal Watch August 2016 Deal Watch August 2016

    540. MEI Pharma (US). Helsinn (CH). Licence. Pracinostat, phase III-ready HDAC inhibitor for treatment of acute myeloid leukaemia. ... 151. Valeant (US). Pharming (NL). Asset acquisition North America. Ruconest (recombinant human C1 esterase inhibitor)

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $150m upfront Novartis gains access to XmAb14045 being developed for acute myeloid leukaemia (AML) and XmAb13676 in development for B-cell malignancies. ... on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics